FINO
FINAL DECISION TRANSACTION PROCESSED BY IB
31/05/2025
Sabia que essa marca já está registrada no Estados Unidos?
Antes de investir em nome, identidade e divulgação, valide risco de colisão e estratégia de registro para não perder tempo nem budget.
Leitura executiva para decisão de naming, protocolo e monitoramento.
Situação USPTO
Tipo de processo
Eventos registrados
Atualização mais recente
Classificação
Tipo de marca
Classes Nice
Data de depósito
Data de registro
Data de expiração
Ação recomendada
Execute uma análise de colidência completa e valide classes antes de qualquer protocolo ou investimento de marca.
Próximo passo
Esses são os detalhes do processo de registro. Mesmo assim, o monitoramento constante é o que garante tranquilidade de que o seu principal ativo continue protegido.
Campos estruturados da autoridade responsável e do histórico oficial.
Data da situação
Última transação
Escritório responsável
Código da situação
Cadastro oficial
Código do desenho
Tipo de titular
Localização do titular
Examinador
Unidade examinadora
Localização atual
Titulares
Representantes
Bradley M. Stohry Reichel Stohry Dean LLP
Classes Nice
Códigos Vienna
Sem códigos Vienna disponíveis.
Produtos e serviços
Classe 1
Chemical products for use in the pharmaceutical industry, namely, chemical additives and preservatives for use in the manufacture of pharmaceuticals; active chemical ingredients for manufacture of pharmaceutical products for treating cardiovascular, digestive, neurological, endocrine, respiratory, immune, muscular, urinary, reproductive, nutritional and skeletal diseases; chemical additives for use as binding agents in the manufacture of pharmaceuticals for treating cardiovascular, digestive, neurological, endocrine, respiratory, immune, muscular, urinary, reproductive, nutritional and skeletal diseases; chemical carrier excipients for use in the manufacture of pharmaceutical preparations; chemical excipients for the manufacture of pharmaceutical preparations; raw material, namely, cellulose microspheres and microspheres made of cellulose, sugar, and starch for use in the manufacture of pharmaceuticals; microcrystalline cellulose microspheres for use in the manufacture of pharmaceuticals; preserving agents for the pharmaceutical industry, namely, antioxidants and antimicrobials for use in the manufacture of pharmaceuticals; carrier excipients for use in the manufacture of pharmaceutical preparations; excipients for pharmaceutical preparation manufacture
Classe 5
Pharmaceutical products, namely, syrups, preparations in the form of granules, and liquid pharmaceutical suspensions, for pharmaceutical purposes for the treatment of cardiovascular, digestive, neurological, endocrine, respiratory, immune, muscular, urinary, reproductive, nutritional and skeletal diseases, and pharmaceutical preparations for the treatment of cardiovascular, digestive, neurological, endocrine, respiratory, immune, muscular, urinary, reproductive, nutritional and skeletal diseases; medicines, namely, syrups, preparations in the form of granules, and liquid pharmaceutical suspensions, for pharmaceutical purposes for the treatment of cardiovascular, digestive, neurological, endocrine, respiratory, immune, muscular, urinary, reproductive, nutritional and skeletal diseases; drug delivery agents consisting of compounds that facilitate delivery of a wide range of pharmaceuticals; drug delivery agents, namely, medicine release agents in the form of gastro-resistant and controlled release microparticles for the controlled release of active ingredients for a wide range of pharmaceutical products; drug delivery agents, namely, medicine delivery agents in the form of granulated powders for the controlled release of active ingredients for a wide range of pharmaceutical products; syrups for pharmaceutical use for the treatment of cardiovascular, digestive, neurological, endocrine, respiratory, immune, muscular, urinary, reproductive, nutritional and skeletal diseases; syrups being medicines for the treatment of cardiovascular, digestive, neurological, endocrine, respiratory, immune, muscular, urinary, reproductive, nutritional and skeletal diseases; syringes pre-filled with syrups for the treatment of cardiovascular, digestive, neurological, endocrine, respiratory, immune, muscular, urinary, reproductive, nutritional and skeletal diseases; medicines being esomeprazole for oral administration; medicines being omeprazole for oral administration; central nervous system stimulants; hormones for medical use; Pharmaceutical products for the treatment of gastrointestinal disorders; soporifics
Classe 42
Pharmaceutical research and development for the pharmaceutical industry; medical and pharmacological research services; research and development services relating to medicines; development of pharmaceutical preparations and medicines; development of pharmaceutical products
Histórico de despachos e eventos da marca no USPTO.
30 publicações encontradas
FINAL DECISION TRANSACTION PROCESSED BY IB
31/05/2025
FINAL DISPOSITION NOTICE SENT TO IB
11/05/2025
FINAL DISPOSITION PROCESSED
11/05/2025
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
10/03/2025
NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB
21/12/2024
NOTICE OF REGISTRATION CONFIRMATION EMAILED
10/12/2024
REGISTERED-PRINCIPAL REGISTER
10/12/2024
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
04/12/2024
NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB
04/12/2024
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
10/09/2024
PUBLISHED FOR OPPOSITION
10/09/2024
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
21/08/2024
APPROVED FOR PUB - PRINCIPAL REGISTER
07/08/2024
EXAMINER'S AMENDMENT ENTERED
07/08/2024
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
07/08/2024
EXAMINERS AMENDMENT E-MAILED
07/08/2024
EXAMINERS AMENDMENT -WRITTEN
07/08/2024
TEAS/EMAIL CORRESPONDENCE ENTERED
22/07/2024
CORRESPONDENCE RECEIVED IN LAW OFFICE
22/07/2024
TEAS RESPONSE TO OFFICE ACTION RECEIVED
22/07/2024
REFUSAL PROCESSED BY IB
14/02/2024
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
25/01/2024
REFUSAL PROCESSED BY MPU
25/01/2024
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
09/01/2024
NON-FINAL ACTION WRITTEN
08/01/2024
ASSIGNED TO EXAMINER
04/01/2024
NEW REPRESENTATIVE AT IB RECEIVED
08/09/2023
APPLICATION FILING RECEIPT MAILED
11/07/2023
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
07/07/2023
SN ASSIGNED FOR SECT 66A APPL FROM IB
06/07/2023
Proteção contínua da sua marca
Vigilância profissional por 24 meses: monitoramos o USPTO por você e alertamos a tempo de você se opor — antes que o conflito vire prejuízo.